Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

942 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.
Ambrosio MR, Lazzi S, Bello GL, Santi R, Porro LD, de Santi MM, Guazzo R, Mundo L, Rigacci L, Kovalchuck S, Onyango N, Fabbri A, Cencini E, Zinzani PL, Zaja F, Angrilli F, Stelitano C, Cabras MG, Spataro G, Bob R, Menter T, Granai M, Cevenini G, Naresh KN, Stein H, Sabattini E, Leoncini L. Ambrosio MR, et al. Among authors: fabbri a. Haematologica. 2019 Jan;104(1):e25-e28. doi: 10.3324/haematol.2018.195958. Epub 2018 Jun 28. Haematologica. 2019. PMID: 29954940 Free PMC article. No abstract available.
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Zinzani PL, et al. Among authors: fabbri a. Lancet Oncol. 2008 Apr;9(4):352-8. doi: 10.1016/S1470-2045(08)70039-1. Epub 2008 Mar 14. Lancet Oncol. 2008. PMID: 18342572 Clinical Trial.
Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenström's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2'-deoxyadenosine (2-CdA) and Rituximab.
Rabascio C, Laszlo D, Andreola G, Saronni L, Radice D, Rigacci L, Fabbri A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Rabascio C, et al. Among authors: fabbri a. Leuk Res. 2010 Apr;34(4):454-7. doi: 10.1016/j.leukres.2009.07.002. Epub 2009 Aug 3. Leuk Res. 2010. PMID: 19647871 Clinical Trial.
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). Ferreri AJ, et al. Among authors: fabbri a. Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18. Lancet. 2009. PMID: 19767089 Free article. Clinical Trial.
Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study.
Laszlo D, Andreola G, Rigacci L, Fabbri A, Rabascio C, Mancuso P, Pruneri G, Radice D, Pinto A, Frigeri F, Calabrese L, Billio A, Bertolini F, Martinelli G. Laszlo D, et al. Among authors: fabbri a. J Clin Oncol. 2010 May 1;28(13):2233-8. doi: 10.1200/JCO.2009.23.6315. Epub 2010 Apr 5. J Clin Oncol. 2010. PMID: 20368573 Clinical Trial.
942 results